businesspress24.com - Breast Cancer Liquid Biopsy Market Size, Share, Trends and Global Forecast 2022
 

Breast Cancer Liquid Biopsy Market Size, Share, Trends and Global Forecast 2022

ID: 1538459

According to the new market research report Breast Cancer Liquid Biopsy Market is expected to reach USD 411.1 million by 2022


(businesspress24) - According to the new market research report Breast Cancer Liquid Biopsy Market is expected to reach USD 411.1 million by 2022 from USD 145.4 million in 2017, at a CAGR of 23.1%. The breast cancer liquid biopsy market is a consolidated market with a large number of companies offering breast cancer liquid biopsy instruments and accessories. In 2016, QIAGEN N.V. (Netherlands), Roche Diagnostics (US), and Illumina, Inc. (US) dominated the breast cancer liquid biopsy market.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=150106081
QIAGEN was the leading player in the breast cancer liquid biopsy market in 2017. The company is a global provider of sample-to-insight solutions that aids in the transformation of biological samples into molecular insights. The company operates through its two business segments, namely, instruments and consumables & related products.
QIAGEN provides solutions to more than 500,000 customers globally, in molecular diagnostics (human healthcare), applied testing (forensics, veterinary testing, and food safety), pharma (pharma and biotech companies), and academia (life sciences research). The company operates in the breast cancer liquid biopsy market through its molecular diagnostics and life science tools customer base segment.
Roche Diagnostics ranked second in the breast cancer liquid biopsy market in 2017. Roche Diagnostics focuses on the discovery, manufacturing, and marketing of medical devices used to screen, diagnose, and monitor therapies. The company operates in the breast cancer liquid biopsy market through its molecular diagnostics segment. The company geographically operates in Europe, the Middle East and Africa, North America, Asia Pacific, and Latin America.
Illumina ranked third in the breast cancer liquid biopsy market in 2017. The company provides sequencing and array-based solutions for genetic analysis. The company develops, manufactures, and markets integrated systems and life science tools for the analysis of genetic variation and biological function. The company operates in the breast cancer liquid biopsy market through its spinoff company




Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=150106081
Some of the major market players in the breast cancer liquid biopsy market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories (US), Myriad Genetics (US), Menarini Silicon Biosystems (Italy), Illumina (US), Cynvenio Biosystems, Inc. (US) Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Fluxion Biosciences, Inc. (US), Biodesix, Inc. (US), Guardant Health, Inc. (US), and Isogen Life Science B.V. (Netherlands).

Contact:
Mr. Shelly Singh
MarketsandMarkets
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: 1-888-600-6441
newsletter(at)marketsandmarkets.com

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Neue Anti Ageing Night Cream von Love Me Green
Tipps vom Experten für eine gesunde Verdauung auf Reisen (FOTO)
Bereitgestellt von Benutzer: RosyW
Datum: 23.08.2019 - 09:48 Uhr
Sprache: Deutsch
News-ID 1538459
Anzahl Zeichen: 3098

Kontakt-Informationen:
Ansprechpartner:
Stadt:


Telefon:

Kategorie:

Gesundheitswesen - Medizin


Meldungsart: Finanzinformation
Versandart: Veröffentlichung
Freigabedatum:
Anmerkungen:


Diese Pressemitteilung wurde bisher 77 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Breast Cancer Liquid Biopsy Market Size, Share, Trends and Global Forecast 2022
"
steht unter der journalistisch-redaktionellen Verantwortung von

MarketsandMarkets™ INC. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von MarketsandMarkets™ INC.



 

Who is online

All members: 10 565
Register today: 0
Register yesterday: 2
Members online: 0
Guests online: 118


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.